09:52 AM EST - Tekmira Pharmaceuticals Corporation : announced that the Company has received verbal notice from the U. S. Food and Drug Administration (FDA) that the TKM-Ebola Phase I healthy volunteer clinical study has been placed on clinical hold. This notice applies only to this study. Tekmira Pharmaceuticals Corporation
shares T.TKM are trading down $2.12 at $12.50.
